Member News

From SCRIP Intelligence: Roche in $1.7bn deal for breast cancer innovator

Roche's Genentech business has agreed to pay $725m up front and up to $1bn in milestone-related payments to acquire Seragon Pharmaceuticals of San Diego, California. Seragon's most advanced product is in Phase I trials, but Roche believes its technology could herald a breakthrough in cancer treatment.

The target company is working on a new generation of breast cancer treatments that Genentech's head of research and early development, Dr Richard Scheller, said "could one day redefine the standard of care for hormone receptor-positive breast cancer."

Seragon has developed a class of medicines called selective estrogen receptor degraders, or SERDs, which it hopes will offer an improved approach to treating hormone-receptor positive breast cancer, and maybe also other cancers linked to the estrogen receptor.

Click here to read this story in full.

« Return to Table of Contents

From SCRIP Intelligence: Genentech leads new breast cancer class with Seragon buy

Genentech has a leading position in HER2-positive breast cancer, so it makes sense for the Roche-owned company to plant its flag in a second, larger part of the breast market with an initial investment of $725m to buy San Diego-based Seragon Pharmaceuticals.


Genentech already dominates the market for HER2-targeting breast cancer therapies with four approved products that generated $7.4bn in worldwide revenue in 2013 – Herceptin (trastuzumab), Perjeta (pertuzumab), Kadcyla (ado-trastuzumab emtansine) and subcutaneous Herceptin. But only 25% of the 229,000 women diagnosed with breast cancer in the US each year have tumors that express the HER2 gene.


Seragon's selective estrogen receptor degraders (SERDs) may offer a new treatment for another 60% of breast cancer patients who have hormone receptor-positive breast cancer, which frequently grows resistant to existing therapies.


Subscribe to SCRIP today to read this story in full & to access the complete SCRIP Intelligence subscription. BIOCOM members: save 10% on your subscription when you subscribe today.

« Return to Table of Contents

DDSTUDIO Named IDEA Finalist

The Industrial Designers Society of America (IDSA) named DDSTUDIO a finalist in the 2014 International Design Excellence Awards (IDEA®) competition—a recognition of design excellence in products, interaction design, service design, strategy, research, concepts and student designs in categories ranging from automobiles and commercial products to medical equipment and home furnishings.

(Continue Reading)

« Return to Table of Contents

Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro™ in Pediatric Patients Undergoing Ear Tube Placement Sur

Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive results from two identical Phase 3 trials of AuriPro™ in a combined total of 532 pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. In both trials, AuriPro achieved the primary efficacy endpoint with statistical significance (p<0.001), showed statistically significant improvements in secondary clinical endpoints and was well tolerated.


(Continue Reading)

« Return to Table of Contents

Technology Entrepreneur Fred Luddy Donates $200,000 to Fund Fellowships at UC San Diego’s Rady School of Management

The Rady School of Management at UC San Diego today announced a $200,000 donation from technology entrepreneur Fred Luddy. The gift will be matched within the $1 million matching fund donation made by the school’s naming donor Ernest Rady in May 2014. The donation from Luddy will fund fellowships that will help attract outstanding MBA students. Fellowships provide merit-based funding for talented students interested in attending the Rady School.

(Continue Reading)

« Return to Table of Contents